CSL: Fully Valued At Current Levels

The share price of CSL jumped almost 14% to $115.90  this week after surprising the market with a big earnings upgrade.

After posting a first-half profit of about USD 800 million, CSL expects net profits for the year ending June 30th to grow between 18 to 20% on a constant currency basis. This forecast included a USD 20 million headwind from unfavorable currency conversions in the AUD/USD.

You’re not a member!  Trial today

However, as positive as the headline and resultant share price rally appear, we suggest that this earnings news needs to be considered within a broader context.

18 months ago the F17 NPAT expectation was $ USD 1.7 billion, 6 months ago it was USD 1.5 billion and the first estimate 2 months ago was  USD 1.28 billion.

In essence, this week’s news that the profit outlook has been raised to USD 1.33 billion is considerably  lower than the earnings figures that  CSL was expecting just 6 months ago…….yet the share price has moved from $90.00 to $114.00.

Based on industry assessments about potential pockets of competition within the immunoglobulins area, the forward earnings trajectory could be revised again over the next few months.

As such, we consider CSL in the $114.00 to 120.00 price range to be full-valued.

Our Algo Engine triggered a buy signal at or near the recent lows of $92.

Chart – CSL

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.